

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re: U.S. Patent No. 6,676,929
Issued: January 13, 2004
To: Thomas J. McMunry et al.
For: Diagnostic Imaging Contrast Agents with Extended Blood Retention

Office of Patent Legal Administration
Mail Stop Hatch-Waxman PTE
Room MDW 7D55
600 Dulany Street (Madison Building)
Alexandria VA 22314

SUPPLEMENT TO REQUEST FOR EXTENSION OF PATENT TERM

Sir:

This is to confirm all inquiries and correspondence relating to the Application for Extension of Patent Term Under 35 U.S.C. § 156, filed February 2, 2009, for the above referenced patent (the "Application") should be directed to Terry Mahn at the address below.

In addition, please replace page 6 of the Application with the enclosed copy of page 6. This correction is requested in order to correct an inadvertent error referencing NDA 21-171. The correct NDA number is 21-711.

Respectfully submitted,


Date: 3/19/2009


Terry G. Mahn

Fish & Richardson P.C.
1425 K Street N.W., 11th Floor
Washington, DC 20005
Telephone: (202) 783-5070
Facsimile: (202) 783-2331

Enclosure: Corrected page 6.

CERTIFICATE OF DELIVERY BY FACSIMILE
I hereby certify that this correspondence along with any attachments is being transmitted by facsimile on the date indicated below to 571-273-7755, Office of Patent Legal Administration, Patent and Trademark Office.

3/19/2009
Date of Delivery

Signature
Jennifer Smith
Printed Name

Patentee : Thomas J. McMurtry et al.
Patent No. : 6,676,929
Issue Date : January 13, 2004
Serial No. : 10/034,522
Filed : December 20, 2001
Page : 6

Attorney's Docket No.: 13498-0005002

10. The relevant dates and information required pursuant to 35 U.S.C. § 156(g) in order to enable the Secretary of Health and Human Services to determine the applicable regulatory review period are as follows:

- (i) Investigational new drug (IND) application 51,172 for VASOVIST was initially submitted on July 19, 1996 and received by the Food and Drug Administration (FDA) on July 22, 1996. The IND effective date was 30 days thereafter on August 21, 1996.
- (ii) New Drug Application (NDA) 21-711 was initially submitted on December 12, 2003 and was received by the FDA on December 15, 2003.
- (iii) The NDA was approved on December 22, 2008.